RADIOACTIVE DIIODOFLUORESCEIN IN DIAGNOSIS AND LOCALIZATION OF CENTRAL NERVOUS SYSTEM TUMORS
- LOYAL DAVIS, M.D.;
- JOHN MARTIN, M.D.;
- MOSES ASHKENAZY, M.D.;
- GEORGE V. LeROY, M.D.;
- THEODORE FIELDS, B.S.
Since this article does not have an abstract, we have provided the first 150 words of the full text.
Excerpt
Radioactive diiodofluorescein has been utilized in the study of 200 patients with the diagnosis of a space-occupying lesion of the central nervous system. We have correlated our observations with the preoperative clinical diagnosis, electroencephalography, pneumography, angiography and surgical and autopsy observations. We have made postoperative and postirradiation tests and, finally, we have correlated all these studies with the histopathological characteristics of the tumors. The results indicate that this radioactive isotope dye test is a valuable diagnostic adjunct in neurosurgical problems not only because of its high degree of accuracy in determining the presence of brain tumors but also because of its relatively precise focal localization. The possibility of prognosticating in a general fashion the relative degree of cellularity and vascularity of the tumor also appears to be feasible.
Fluorescein was believed to have a special affinity for tumor cells as early as 1911, at which time Wasserman, Keysser and Wasserman
Footnotes
-
Aided by the Grunow Surgical Fund.
-
The radioiodine used in this study was supplied by the Isotope Division, Oak Ridge National Laboratory, United States Atomic Energy Commission.
-
Reviewed in the Veterans Administration and published with the approval of the Chief Medical Director. The statements and conclusions published by the authors are the result of their own studies and do not necessarily reflect the opinion or policy of the Veterans Administration.
